Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

The results highlight an in vivo patient-derived xenograft (PDX) model of relapsed/refractory T-PLL that reproduced key human clinicopathological features of the disease. In this model, SLS009 ...

A team of researchers from Penn State College of Medicine found a new target for treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1). They determined that blocking a class of ...

A team of researchers found a potential new target for treating diseases associated with human T-cell leukemia virus type 1, including a specific type of leukemia and a neuroinflammatory disease ...

Researchers announced a significant paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of cancer, to one frequently driven by ...

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial The global incidence of ...

Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukemia.

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood 2025 Jul 30:blood.2025028730. doi: 10.1182/blood.2025028730 Online ahead of ...